Project 3: Translational Model of Cell-Based Therapy for Myocardial Infarction. Project 3 proposes to develop and test in vivo, cell-based therapies to improve cardiac function following infarction. Two therapeutic approaches will be studied: 1) Injection of immortalized, clonal populations of marrow stromal cells (MSC), or their secreted products, to facilitate endogenous recovery. 2) Engraftment of exogenous cardiomyocytes (CMs), with/without MSC or MSC-derived factors. The exogenous CMs will be harvested from prenatal hearts or differentiated from either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC). These studies will be performed first in a rat model, which is well developed by investigators in this program, and allows for a sufficiently large number of animals to test several variables. Once a beneficial protocol is identified in the rat model it will be applied to the canine model. Torok-Storb and colleagues have extensive experience with cell transplantation in the dog model. In particular the issues of allograft rejection and the benefits and consequences of immunosuppression accurately reflect these same complications in patients, therefore strategies to address these issues will be clinically relevant. This stepwise plan, from rats to dogs, will limit the number of dogs required. There are three specific aims to address these goals.
Aim 1 proposes to generate and characterize cardiomyocytes (CM) derived from canine embryonic stem cells (ESC) and from induced pluripotent stem cells (iPSC).
Aim 2 will test the hypothesis that MSC facilitate endogenous repair and revascularization, induce tolerance, and promote engraftment of cardiomyocytes in the rat model. For this purpose immortalized and cloned MSC lines have been generated to provide reagents that can be well characterized and provide a consistent product for investigation. Dog MSC lines functionally analogous to rat MSC lines will be identified and used in Aim 3 to repair an infarcted heart in the dog model. These studies will serve to establish a robust large animal model for developing protocols and testing the efficacy and safety of cell based therapies for treating myocardial infarcts.

Public Health Relevance

The proposed studies in this project will serve to establish a robust large animal model for developing protocols and testing the long-term efficacy and safety of cell based therapies for treating myocardial infarcts.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL094374-03
Application #
8380423
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
3
Fiscal Year
2012
Total Cost
$520,158
Indirect Cost
$105,345
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Hofsteen, Peter; Robitaille, Aaron M; Chapman, Daniel Patrick et al. (2016) Quantitative proteomics identify DAB2 as a cardiac developmental regulator that inhibits WNT/β-catenin signaling. Proc Natl Acad Sci U S A 113:1002-7
Ruan, Jia-Ling; Tulloch, Nathaniel L; Razumova, Maria V et al. (2016) Mechanical Stress Conditioning and Electrical Stimulation Promote Contractility and Force Maturation of Induced Pluripotent Stem Cell-Derived Human Cardiac Tissue. Circulation 134:1557-1567
Qin, Wan; Roberts, Meredith A; Qi, Xiaoli et al. (2016) Depth-resolved 3D visualization of coronary microvasculature with optical microangiography. Phys Med Biol 61:7536-7550
Pioner, Josè Manuel; Racca, Alice W; Klaiman, Jordan M et al. (2016) Isolation and Mechanical Measurements of Myofibrils from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cell Reports 6:885-96
Kolwicz Jr, Stephen C; Odom, Guy L; Nowakowski, Sarah G et al. (2016) AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther 24:240-50
Hartman, Matthew E; Dai, Dao-Fu; Laflamme, Michael A (2016) Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair. Adv Drug Deliv Rev 96:3-17
Carson, Daniel; Hnilova, Marketa; Yang, Xiulan et al. (2016) Nanotopography-Induced Structural Anisotropy and Sarcomere Development in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells. ACS Appl Mater Interfaces 8:21923-32
Thies, R Scott; Murry, Charles E (2015) The advancement of human pluripotent stem cell-derived therapies into the clinic. Development 142:3077-84
Palpant, Nathan J; Hofsteen, Peter; Pabon, Lil et al. (2015) Cardiac development in zebrafish and human embryonic stem cells is inhibited by exposure to tobacco cigarettes and e-cigarettes. PLoS One 10:e0126259
Ruan, Jia-Ling; Tulloch, Nathaniel L; Saiget, Mark et al. (2015) Mechanical Stress Promotes Maturation of Human Myocardium From Pluripotent Stem Cell-Derived Progenitors. Stem Cells 33:2148-57

Showing the most recent 10 out of 75 publications